Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

elc group s.r.o., pobrezni 394/12, karlin, prag, Češka - ramipril bisoprololfumarat - kapsula, tvrda - urbroj: jedna tvrda kapsula sadrži 5 mg ramiprila i 2.5 mg bisoprololfumarata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

elc group s.r.o., pobrezni 394/12, karlin, prag, Češka - ramipril bisoprololfumarat - kapsula, tvrda - urbroj: jedna tvrda kapsula sadrži 5 mg ramiprila i 5 mg bisoprololfumarata

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international n.v.   - bosentan (as monohydrate) - scleroderma, systemic; hypertension, pulmonary - Гипотензивные, - liječenje plućne arterijske hipertenzije (pah) za poboljšanje sposobnosti vježbanja i simptoma u bolesnika s who funkcionalnom klasom iii. efficacy has been shown in: , primary (idiopathic and familial) pah;, pah secondary to scleroderma without significant interstitial pulmonary disease;, pah associated with congenital systemic-to-pulmonary shunts and eisenmenger's physiology. neka poboljšanja su također je prikazano u bolesnika s lag, koji funkcionalna klasa ii. tracleer također je istakao smanjenje broja novih digitalne ulkusa kod pacijenata sa sistemske склеродермией i tijeku bolesti digitalni ulkus .

Europska Unija - hrvatski - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - ambrisentan - hipertenzija, plućna - Гипотензивные, - volibris is indicated for treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment (see section 5.  efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease. volibris is indicated for treatment of pah in adolescents and children (aged 8 to less than 18 years) of who functional class (fc) ii to iii including use in combination treatment. efficacy has been shown in ipah, familial, corrected congenital and in pah associated with connective tissue disease (see section 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - lijekovi za liječenje bolesti kostiju - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

farmal d.d., branitelja domovinskog rata 8, ludbreg - simvastatinum - filmom obložena tableta - 10 mg - urbroj: 1 filmom obložena tableta sadrži 10 mg simvastatina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

farmal d.d., branitelja domovinskog rata 8, ludbreg - simvastatinum - filmom obložena tableta - 20 mg - urbroj: 1 filmom obložena tableta sadrži 20 mg simvastatina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

farmal d.d., branitelja domovinskog rata 8, ludbreg - simvastatinum - filmom obložena tableta - 40 mg - urbroj: 1 filmom obložena tableta sadrži 40 mg simvastatina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

actavis group ptc ehf, reykjavikurvegur 76-78, hafnarfjordur, island - ezetimibum, simvastatinum - tableta - 10 mg/10 mg - urbroj: svaka tableta sadrži 10 mg ezetimiba i 10 mg simvastatina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

actavis group ptc ehf, reykjavikurvegur 76-78, hafnarfjordur, island - ezetimibum, simvastatinum - tableta - 10 mg/20 mg - urbroj: svaka tableta sadrži 10 mg ezetimiba i 20 mg simvastatina